Drug Trial Radar · NCT06140836
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
190
Planned (sponsor's estimate)
Start
Dec 21, 2023
Primary completion
Feb 16, 2027
Study completion Mar 15, 2027
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Zai Lab (Shanghai) Co., Ltd.
- First posted
- Nov 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
RepotrectinibDrug
Specified dose on specified days
CrizotinibDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) as per Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Up to approximately 41 months
Locations
120 sites in 21 countries. Site status is shown where the registry gives one.
Local Institution - 0075
Boston, Massachusetts
Local Institution - 0201
Boston, Massachusetts
Local Institution - 0210
Mineola, New York
Local Institution - 0134
New York, New York
Local Institution - 0106
Buenos Aires, Argentina
Local Institution - 0207
Buenos Aires, Argentina
Local Institution - 0093
Córdoba, Argentina
Local Institution - 0092
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Instituto Alexander Fleming
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Local Institution - 0091
ABB, Buenos Aires F.D., Argentina
Local Institution - 0041
Vienna, Austria
Local Institution - 0098
Rio de Janeiro, Brazil
Local Institution - 0108
Rio de Janeiro, Brazil
Local Institution - 0032
São Paulo, Brazil
Local Institution - 0114
São Paulo, Brazil
Local Institution - 0073
Belo Horizonte, Minas Gerais, Brazil
Local Institution - 0033
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution - 0034
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution - 0029
Barretos, São Paulo, Brazil
Local Institution - 0037
São José do Rio Preto, São Paulo, Brazil
Local Institution - 0209
São Paulo, São Paulo, Brazil
Local Institution - 0147
São Paulo, São Paulo, Brazil
Local Institution - 0002
Toronto, Ontario, Canada
Local Institution - 0123
Trois-Rivières, Quebec, Canada
Fundacion Arturo Lopez Perez (FALP)
Santiago, Santiago Metropolitan, Chile
Local Institution - 0096
Viña del Mar, Valparaiso, Chile
Local Institution - 0168
Beijing, Beijing Municipality, China
Local Institution - 0185
Chongqing, Chongqing Municipality, China
Local Institution - 0169
Xiamen, Fujian, China
Local Institution - 0180
Guangzhou, Guangdong, China
Local Institution - 0194
Nanning, Guangxi, China
Local Institution - 0171
Harbin, Heilongjiang, China
Local Institution - 0166
Zhengzhou, Henan, China
Local Institution - 0181
Wuhan, Hubei, China
Local Institution - 0184
Changsha, Hunan, China
Local Institution - 0193
Nanjing, Jiangsu, China
Local Institution - 0202
Nanchang, Jiangxi, China
Local Institution - 0178
Changchun, Jilin, China
Local Institution - 0183
Xi'an, Shaanxi, China
Local Institution - 0186
Jinan, Shandong, China
Showing 40 of 120 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.